Kiniksa Pharmaceuticals Ownership | Who Owns Kiniksa Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Kiniksa Pharmaceuticals Ownership Summary


Kiniksa Pharmaceuticals is owned by 9.91% institutional investors, 3.53% insiders, and 86.56% retail investors. Fmr is the largest institutional shareholder, holding 9.20% of KNSA shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.72% of its assets in Kiniksa Pharmaceuticals shares.

KNSA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKiniksa Pharmaceuticals9.91%3.53%86.56%
SectorHealthcare Stocks 232.80%10.63%-143.43%
IndustryBiotech Stocks 379.48%10.37%-289.85%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr6.82M9.20%$328.56M
Rubric capital management lp3.75M5.05%$180.56M
Vanguard group3.11M4.23%$128.41M
Baker bros. advisors lp2.83M3.81%$136.08M
Tang capital management2.26M3.05%$108.81M
Acadian asset management1.34M1.80%$64.32M
Morgan stanley997.79K1.34%$48.04M
D. e. shaw959.26K1.29%$46.19M
Arrowstreet capital, limited partnership892.67K1.20%$42.98M
Dimensional fund advisors lp811.92K1.09%$39.09M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tang capital management2.26M5.53%$108.81M
Lion point capital, lp23.40K5.16%$908.62K
Rubric capital management lp3.75M1.91%$180.56M
Essex investment management249.28K1.90%$12.00M
Rice hall james & associates608.42K1.63%$29.30M
Parkman healthcare partners259.18K1.29%$12.48M
Penn capital management company301.99K1.13%$14.56M
Quantessence capital4.76K1.12%$229.24K
Cannon global investment management11.00K1.03%$529.65K
Soleus capital management521.35K1.02%$25.10M

Top Buyers

HolderShares% AssetsChange
Fmr6.82M0.02%5.18M
Balyasny asset management499.79K0.03%499.79K
Rubric capital management lp3.75M1.91%421.35K
Susquehanna group, llp383.81K0.00%340.91K
Janus henderson group481.02K0.01%327.60K

Top Sellers

HolderShares% AssetsChange
Blackrock---4.19M
Hhlr advisors---1.58M
Fairmount funds management---1.32M
Nuveen asset management---831.10K
Goldman sachs group174.90K0.00%-654.52K

New Positions

HolderShares% AssetsChangeValue
Balyasny asset management499.79K0.03%499.79K$24.06M
Penn capital management company301.99K1.13%301.99K$14.56M
New york state common retirement fund209.62K0.01%209.62K$10.09M
Adage capital partners gp59.00K0.00%59.00K$2.29M
Brevan howard capital management lp53.88K0.02%53.88K$2.59M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Clearstead advisors-2.00
Optima capital-18.00
Riggs asset managment-30.00
Nelson, van denburg & campbell wealth management group-34.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202561-70.67%7,296,166-82.12%90.32%27-74.53%19-72.86%
Sep 30, 202571-62.83%6,310,956-84.11%80.29%41-63.06%20-67.74%
Jun 30, 20251906.74%39,714,3312.46%541.90%11015.79%6212.73%
Mar 31, 20251789.20%39,838,0562.13%541.84%9521.79%55-5.17%
Dec 31, 20241-50.00%98,093-23.09%-432.56%1---

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.25M1.72%-
Vanguard Total Stock Mkt Idx Inv1.29M1.69%27.96K
Pictet Biotech965.39K1.36%965.39K
iShares Russell 2000 ETF971.72K1.33%-
Vanguard Small Cap Index955.02K1.25%32.48K
Fidelity Select Health Care800.00K1.04%-
Fidelity Select Biotechnology637.60K0.83%370.10K
Vanguard Institutional Extnd Mkt Idx Tr567.21K0.80%795.00
Fidelity Small Cap Growth581.26K0.76%18.22K
Strategic Advisers Fidelity US TtlStk561.98K0.73%39.00K

Recent Insider Transactions


DateNameRoleActivityValue
May 01, 2026Paolini John F. CHIEF MEDICAL OFFICERSell$1.14M
May 01, 2026Paolini John F. CHIEF MEDICAL OFFICERSell$2.00M
May 01, 2026Patel Sanj K CHAIRMAN & CEOSell$2.62M
Apr 28, 2026Patel Sanj K CHAIRMAN & CEOSell$12.67M
Apr 28, 2026Patel Sanj K CHAIRMAN & CEOSell$5.85M

Insider Transactions Trends


DateBuySell
2026 Q2-12
2026 Q1-12
2025 Q4-17
2025 Q3-19
2025 Q2-29

KNSA Ownership FAQ


Who Owns Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals shareholders are primarily institutional investors at 9.91%, followed by 3.53% insiders and 86.56% retail investors. The average institutional ownership in Kiniksa Pharmaceuticals's industry, Biotech Stocks , is 379.48%, which Kiniksa Pharmaceuticals falls below.

Who owns the most shares of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals’s largest shareholders are Fmr (6.82M shares, 9.20%), Rubric capital management lp (3.75M shares, 5.05%), and Vanguard group (3.11M shares, 4.23%). Together, they hold 18.48% of Kiniksa Pharmaceuticals’s total shares outstanding.

Does Blackrock own Kiniksa Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Kiniksa Pharmaceuticals.

Who is Kiniksa Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tang capital management is Kiniksa Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.53% of its assets in 2.26M Kiniksa Pharmaceuticals shares, valued at 108.81M$.

Who is the top mutual fund holder of Kiniksa Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Kiniksa Pharmaceuticals shares, with 1.72% of its total shares outstanding invested in 1.25M Kiniksa Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools